Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Takeaway - MDSpire
From the Journals

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

Share

  • 1

    Phase III KEYNOTE-905/EV-303 trial studied enfortumab vedotin plus pembrolizumab.

  • 2

    Improved event-free survival: 74.7% vs 39.4%.

  • 3

    Overall survival at 2 years: 79.7% for therapy group.

  • 4

    Pathologic complete response: 57.1% in therapy group.

  • 5

    Adverse events significantly higher in therapy group, with urinary infections common.

  • 6

    Funding provided by Merck Sharp and Dohme.

  • 7

    The study indicates safety and efficacy of novel therapy in nearly cisplatin-ineligible patients.

Original Source(s)

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

  • by Matthew Stenger

  • April 7, 2026

Related Content

Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?

Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approac...

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...